ClinicalTrials.gg
TerminatedNCT04581824Updated Aug 8, 2025Results posted

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Dostarlimab and Pembrolizumab in Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline. Terminated at 58 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial terminated by GSK for strategic reasons, after all participants completed treatment. This decision was not based on a safety concern

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.

Enrollment
14th of 47
243 · median 88
Started
2020
with 2 others
Phase 2
18 of 54
none open now
Registered
45th of 54
by date

Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 14th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2020, is one of 18 in phase 2, and was the 45th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, or all of them as a file.
02

Study summary

NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis. Dostarlimab is an immunoglobulin G (IgG)4 kappa humanized monoclonal antibody (mAb) that binds with high affinity to programmed cell death protein 1 (PD 1), resulting in inhibition of binding to programmed death ligand 1 (PD L1) and programmed death ligand 2 (PD L2). This study aims to compare the efficacy and safety PD-1 inhibitors dostarlimab and pembrolizumab, when administered in combination with chemotherapy (pemetrexed, cisplatin and carboplatin), in participants with non-squamous NSCLC without a known sensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or receptor tyrosine kinase-1 (ROS-1) mutation, BRAF V600E mutation, or other genomic aberration for which an approved targeted therapy is available. A total of approximately 240 participants will be enrolled in the study for a period of 5 years.

03

Conditions studied

  • Lung Cancer, Non-Small Cell

Keywords

  • Non small cell lung cancer
  • Dostarlimab
  • Pembrolizumab
  • Pemetrexed
  • Carboplatin
  • Cisplatin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be greater than equal to (>=) 18 years old, must be able to understand the study procedures, and agrees to participate in the study by providing written which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Participant has - or cytologically-confirmed non-squamous NSCLC with documented absence of a sensitizing EGFR, ALK, ROS-1, or BRAFV600E mutation or other genomic aberration for which an approved targeted therapy is available. Mixed tumors will be categorized by the predominant cell type; if the tumor has predominantly squamous cell histology or if small cell elements are present, the participant is ineligible.
  • Participants must have , that is (i.e.) presenting with at least 1 measurable lesion per v1.1 as determined by the local site Investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions and if there are other target lesions. If there is only 1 target lesion that was previously irradiated, the participant is not eligible.
  • Participant has documented PD L1 status by the 22C3 pharmDx assay (Agilent/Dako). If no prior PD L1 result is available at the time of Screening, the participant can be tested locally using the stated method, or central PD L1 testing can be completed. Results are needed for stratification and must be available prior to randomization.
  • Participant has an performance status score of 0 or 1.
  • Participant has a of at least 3 months.
  • Participant has adequate organ function.
  • Participant has recovered to Grade less than equal to (\<=)1 from any prior treatment related toxicities at the time of randomization. A participant with Grade 2 alopecia is an exception to this criterion and may qualify for this study.
  • use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Male participants are eligible to participate if they agree to the following during the Treatment Period and for at least 150 days after the last dose of study treatment:
  • Refrain from donating sperm plus, either:
  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.
  • Must agree to use contraception/barrier as follows:
  • Agree to use a male condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception, as a condom may break or leak) when having sexual intercourse with a woman of (WOCBP) who is not currently pregnant.
  • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and 1 of the following conditions applies:
  • Is a woman of non childbearing potential (WONCBP),
  • Is a WOCBP, using a contraceptive method that is highly effective (with a failure rate of \<1% per year and, preferably, with low user dependency) during the Treatment Period and for at least 180 days after the last dose of study treatment and agrees not to donate eggs (ova or oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the potential for contraceptive method failure ( for example [e.g.], noncompliance and recently initiated) in relationship to the first dose of study treatment.
  • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, as required by local guidelines) within 72 hours before the first dose of study treatment. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

Exclusion criteria

Exclusion Criteria:

  • Participant has received prior systemic therapy for the treatment of NSCLC. Participants who have received or adjuvant chemotherapy are eligible if the neoadjuvant/adjuvant therapy was completed at least 12 months prior to the development of metastatic disease.
  • Participant has received prior therapy with a PD (L)1 or PD L2 inhibitor, a cytotoxic T lymphocyte associated protein 4 (CTLA 4) inhibitor, a T cell immunoglobulin and mucin domain containing 3 (TIM 3) inhibitor, or any other immunotherapy agent (eg, OX40) for the treatment of cancer.
  • Participant has received radiation to the lung that is >30 Gray (Gy) within 6 months of the first dose of study treatment.
  • Participant has completed palliative radiotherapy within 7 days of the first dose of study treatment.
  • Participant is ineligible if any of the following hepatic characteristics are present:
  • (ALT) >2.5 times (ULN) without liver metastases/tumor infiltration.
  • ALT >5 times ULN with liver metastases/tumor infiltration.
  • >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%)
  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per Investigator assessment)
  • Participant has a interval (QTc) >450 milliseconds (msec) (or QTc >480 msec for participants with bundle branch block).
  • Participant has had major surgery within 3 weeks of the first dose of study treatment or has not adequately recovered from any AEs (Grade \<=1) and/or complications from any major surgery. Surgical implantation of a port catheter is not exclusionary.
  • Participant has an additional or a history of prior malignancy, with the exception of adequately treated basal or squamous skin cancer, cervical carcinoma in situ, or bladder carcinoma in situ without evidence of disease, or had a malignancy treated with curative intent and with no evidence of disease recurrence for 5 years since the initiation of that therapy.
  • Participant has known active and/or . Participants who have received prior therapy for their brain metastases and have radiographically stable central nervous system disease may participate, provided they are neurologically stable for at least 2 weeks before study entry and must be off within 3 days prior to the first dose of study treatment. Stable brain metastases by this definition should be established prior to the first dose of study treatment. Participants with known untreated, asymptomatic brain metastases (i.e., no neurological symptoms, no requirements for corticosteroids, no or minimal surrounding edema, and no lesions >1.5 centimeters [cm]) may participate, but will require regular imaging of the brain as a site of disease.
  • Participant has tested positive for the presence of surface antigen or has a positive antibody test result at Screening, or within 3 months prior to first dose of study treatment. For potent agents, participants who test positive for the presence of hepatitis B core antibody should also be excluded.
  • Participant has an active infection requiring systemic therapy within 1 week prior to the anticipated first dose of study treatment.
  • Participant has known (HIV) (positive for HIV 1 or HIV 2 antibodies).
  • Participant has active disease that required systemic treatment in the past 2 years, is immunocompromised in the opinion of the Investigator, or is receiving systemic immunosuppressive treatment. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
  • Participant has received systemic steroid therapy within 3 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.
  • Participant has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment of these conditions (including therapeutic thoraco or paracentesis) is eligible.
  • Participant has current interstitial lung disease, current pneumonitis, or a history of pneumonitis that required the use of oral or IV glucocorticoids to assist with management. Lymphangitic spread of the NSCLC is not exclusionary.
  • Participant has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the study results, interfere with their participation for the full duration of the study treatment, or indicate it is not in the best interest of the participant to participate, in the opinion of the Investigator.
  • Participant has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or peritoneal carcinomatosis.
  • Participant has preexisting peripheral neuropathy that is Grade >=2 by National Cancer Institute (NCI CTCAE) v5.0 criteria.
  • Participant has received a within 30 days of the first dose of study treatment. Seasonal flu vaccines that do not contain live virus are permitted.
  • Participant does not meet requirements per local prescribing guidelines for receiving treatment with either pemetrexed and cisplatin or carboplatin.
  • Participant has sensitivity to any of the study treatments, or components thereof, or a history of drug or other allergy that, in the opinion of the Investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.
  • Participant is unable to interrupt aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs), other than an aspirin dose \<=1.3 gram (g) per day, for a 5 day period (8 day period for long acting agents, such as piroxicam).
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Participants receiving dostarlimab plus chemotherapy

    Participants will receive dostarlimab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.

    Drug: Dostarlimab · Drug: Chemotherapy

  • Active comparator
    Participants receiving pembrolizumab plus chemotherapy

    Participants will receive pembrolizumab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.

    Drug: Pembrolizumab · Drug: Chemotherapy

Interventions

  • Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).

  • Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).

  • DrugChemotherapy

    Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days). Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision. Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had a confirmed complete response (CR) or confirmed partial response (PR) as their best overall response (BOR) recorded from the date of randomization until disease progression or initiation of new anti-cancer therapy, whichever is earlier based on blinded independent central review (BICR) evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters (e.g., percent change from baseline).

    Time frame: Up to approximately 20 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death by any cause.

    Time frame: Up to approximately 46 months

  2. Progression-free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of disease progression (PD) or death by any cause, whichever occurs first. PFS was evaluated using Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 based on Investigator assessment. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

    Time frame: Up to approximately 46 months

  3. Number of Participants With Treatment-emergent Adverse Event (TEAEs), TEAEs Leading to Death and TEAEs Leading to Treatment Discontinuation

    AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. Number of participants with TEAEs, TEAEs leading to death, and TEAEs leading to treatment discontinuation are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).

    Time frame: Up to 46 months

  4. Number of Participants With Treatment Emergent Immune-related Adverse Event (irAE)

    The irAEs are events which are severe or fatal and can occur in participants treated with monoclonal antibodies directed against immune checkpoints, including pembrolizumab and dostarlimab. While irAEs (eg, diarrhea/colitis, pneumonitis, nephritis, hypophysitis, adrenalitis, thyroiditis, severe skin reactions, uveitis, myocarditis, and hepatotoxicity) usually occur during treatment, symptoms can also manifest after discontinuation of treatment. AEs were coded using the MedDRA dictionary.

    Time frame: Up to 46 months

  5. Number of Participants With Serious AEs

    An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the above outcomes. SAEs are subset of AEs. AEs were coded using the MedDRA dictionary.

    Time frame: Up to approximately 46 months

  6. Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 30 to 110 units per liter (U/L) (Amylase); 4. 5 to 5. 6 milligram/deciliters (mg/dL) (Calcium); 96 to 100 milliequivalents (mEq)/ L (Chloride); 2. 5 to 4.5 mg/dL (Phosphate); 6 to 8.3 grams/L (protein); 6 to 24 millimoles/L (Urea) and 7 to 20 mg/dL (Urea nitrogen). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 46 months

  7. Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils); 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit); 80-100 femtoliters (fl) (erythrocytes \[referred as Ery\] mean corpuscular volume (EMCV)); 2 to 8 percentage of WBC (monocytes); and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 46 months

  8. Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

    Urine samples were collected to assess urine Bilirubin, glucose, ketones, Leukocyte Esterase, Nitrite, occult blood and Protein using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as No Change/Decreased, Increase to TRACE, Increase to +, Increase to ++, Increase to +++ and Increase to ++++. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

    Time frame: Up to approximately 46 months

  9. Change From Baseline (CFB) in Thyroid Functions: Free Triiodothyronine (T3) and Free Thyroxine (T4)

    Blood samples were collected for the assessment Free Triiodothyronine (T3) and Free Thyroxine (T4).

    Time frame: Up to approximately 46 months

  10. Change From Baseline in Thyroid Function: Thyrotropin (TSH)

    Blood samples were collected for the assessment of Thyroid Function Thyrotropin (TSH).

    Time frame: Up to approximately 46 months

  11. Change From Baseline in Thyroid Functions: Triiodothyronine (T3) and Thyroxine (T4)

    Blood samples were collected for the assessment of Triiodothyronine (T3) and Thyroxine (T4).

    Time frame: Up to approximately 46 months

  12. Number of Participants With Worst-case Grade Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

    DBP and SBP were measured in a semi-supine position after 5 minutes rest. Grades were derived based on numeric criteria as defined in Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Systolic Blood Pressure (SBP): Grade 0 (\<120 Millimetre of mercury (mmHg)), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). Diastolic Blood Pressure (DBP): Grade 0 (\<80 mmHg), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Only those participants with grade increase have been presented. Participants with missing Baseline values were assumed to have a Baseline value of G0.

    Time frame: Up to approximately 46 months

  13. Number of Participants With Worst Case Pulse Rate Results Post-Baseline Relative to Baseline Based on Potential Clinical Importance (PCI)

    Normal range of Pulse Rate was 60 to 100 beats/min. Participants were counted in worst case category that their value changes to low, to within \[w/in\] Range or No Change \[NC\] or high, unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category.

    Time frame: Up to approximately 46 months

  14. Number of Participants With Worst-Case Post-Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status

    Performance status was assessed using the ECOG scale (Grade 0-5). Grades: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory, able to carry out work of light nature. 2: Ambulatory, capable of self-care, unable to carry out work activities. Up and about more than 50% waking hours. 3: Capable of limited self-care, confined to bed/chair more than 50% waking hours. 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed/chair. 5: Dead.

    Time frame: Up to approximately 46 months

  15. Mean Change From Baseline in Electrocardiogram (ECG) Parameters

    Participants were in a supine or semi recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs were recorded. Single 12-lead ECG was recorded using an ECG machine. PR, QRS, QT, QTcF, and RR intervals were recorded

    Time frame: Baseline (Day 1), Cycle 1 Day 1, and end of treatment (Up to approximately 46 months)

  16. Mean Change From Baseline in ECG Mean Heart Rate

    Participants were in a supine or semi recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs were recorded. Single 12-lead ECG was recorded using an ECG machine. Mean Heart rate were recorded.

    Time frame: Baseline (Day 1), Cycle 1 Day 1, and end of treatment (Up to approximately 46 months)

  17. Number Participant Who Used Concomitant Medications

    Number of participants received concomitant medications were summarized.

    Time frame: Up to approximately 46 months

07

Results

Posted Sep 18, 2023

Participant flow

Participant flow — Overall Study
MilestoneDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Started121122
Completed8192
Not completed4030
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject27
Withdrew: Study terminated by sponsor3723

Outcome measures

SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death by any cause.

Time frame:
Up to approximately 46 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Overall Survival (OS)20.2 (14.5 to 27.3)15.9 (11.6 to 19.3)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of disease progression (PD) or death by any cause, whichever occurs first. PFS was evaluated using Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 based on Investigator assessment. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

Time frame:
Up to approximately 46 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Progression-free Survival (PFS)8.8 (6.9 to 11.0)6.8 (4.9 to 7.1)
SecondaryNumber of Participants With Treatment-emergent Adverse Event (TEAEs), TEAEs Leading to Death and TEAEs Leading to Treatment Discontinuation

AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. Number of participants with TEAEs, TEAEs leading to death, and TEAEs leading to treatment discontinuation are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).

Time frame:
Up to 46 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Event (TEAEs), TEAEs Leading to Death and TEAEs Leading to Treatment Discontinuation
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
TEAEs119119
TEAEs leading to death1712
TEAEs leading to treatment discontinuation3546
SecondaryNumber of Participants With Treatment Emergent Immune-related Adverse Event (irAE)

The irAEs are events which are severe or fatal and can occur in participants treated with monoclonal antibodies directed against immune checkpoints, including pembrolizumab and dostarlimab. While irAEs (eg, diarrhea/colitis, pneumonitis, nephritis, hypophysitis, adrenalitis, thyroiditis, severe skin reactions, uveitis, myocarditis, and hepatotoxicity) usually occur during treatment, symptoms can also manifest after discontinuation of treatment. AEs were coded using the MedDRA dictionary.

Time frame:
Up to 46 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Immune-related Adverse Event (irAE)
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Number of Participants With Treatment Emergent Immune-related Adverse Event (irAE)3847
SecondaryNumber of Participants With Serious AEs

An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the above outcomes. SAEs are subset of AEs. AEs were coded using the MedDRA dictionary.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants With Serious AEs
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Number of Participants With Serious AEs5161
SecondaryNumber of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 30 to 110 units per liter (U/L) (Amylase); 4. 5 to 5. 6 milligram/deciliters (mg/dL) (Calcium); 96 to 100 milliequivalents (mEq)/ L (Chloride); 2. 5 to 4.5 mg/dL (Phosphate); 6 to 8.3 grams/L (protein); 6 to 24 millimoles/L (Urea) and 7 to 20 mg/dL (Urea nitrogen). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Amylase, To Low811
Amylase, To Normal or No Change7676
Amylase, To High3430
Calcium, To Low4239
Calcium, To Normal or No Change6065
Calcium, To High2516
Chloride, To Low3426
Chloride, To Normal or No Change6569
Chloride, To High2225
Phosphate, To Low3222
Phosphate, To Normal or No Change6470
Phosphate, To High2628
Protein, To Low5254
Protein, To Normal or No Change5556
Protein, To High126
Urea, To Low711
Urea, To Normal or No Change4345
Urea, To High4137
Urea Nitrogen, To Low56
Urea Nitrogen, To Normal or No Change2617
Urea Nitrogen, To High2013
SecondaryNumber of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils); 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit); 80-100 femtoliters (fl) (erythrocytes \[referred as Ery\] mean corpuscular volume (EMCV)); 2 to 8 percentage of WBC (monocytes); and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Basophils, To Low129
Basophils, To Normal or No Change7275
Basophils, To High1919
Hematocrit, To Low7364
Hematocrit, To Normal or No Change4350
Hematocrit, To High31
EMCV, To Low611
EMCV, To Normal or No Change5954
EMCV, To High5754
Monocytes, To Low2321
Monocytes, To Normal or No Change4142
Monocytes, To High4643
Erythrocytes, To Low7379
Erythrocytes, To Normal or No Change4434
Erythrocytes, To High26
SecondaryNumber of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

Urine samples were collected to assess urine Bilirubin, glucose, ketones, Leukocyte Esterase, Nitrite, occult blood and Protein using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as No Change/Decreased, Increase to TRACE, Increase to +, Increase to ++, Increase to +++ and Increase to ++++. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Bilirubin, No Change/Decreased8666
Bilirubin, Increase to TRACE00
Bilirubin, Increase to +43
Bilirubin, Increase to ++00
Bilirubin, Increase to +++00
Bilirubin, Increase to ++++00
Glucose, No Change/Decreased7957
Glucose, Increase to TRACE21
Glucose, Increase to +88
Glucose, Increase to ++12
Glucose, Increase to +++12
Glucose, Increase to ++++21
Ketones, No Change/Decreased8158
Ketones, Increase to TRACE43
Ketones, Increase to +87
Ketones, Increase to ++02
Ketones, Increase to +++01
Ketones, Increase to ++++00
Leukocyte Esterase, No Change/Decreased7555
Leukocyte Esterase, Increase to TRACE12
Leukocyte Esterase, Increase to +1110
Leukocyte Esterase, Increase to ++20
Leukocyte Esterase, Increase to +++13
Leukocyte Esterase, Increase to ++++10
Nitrite, No Change/Decreased9070
Nitrite, Increase to TRACE00
Nitrite, Increase to +31
Nitrite, Increase to ++00
Nitrite, Increase to +++00
Nitrite, Increase to ++++00
Occult Blood, No Change/Decreased7757
Occult Blood, Increase to TRACE63
Occult Blood, Increase to +68
Occult Blood, Increase to ++33
Occult Blood, Increase to +++00
Occult Blood, Increase to ++++00
Protein, No Change/Decreased7153
Protein, Increase to TRACE73
Protein, Increase to +1410
Protein, Increase to ++03
Protein, Increase to +++11
Protein, Increase to ++++00
SecondaryChange From Baseline (CFB) in Thyroid Functions: Free Triiodothyronine (T3) and Free Thyroxine (T4)

Blood samples were collected for the assessment Free Triiodothyronine (T3) and Free Thyroxine (T4).

Time frame:
Up to approximately 46 months
Reported as:
Mean · Picomoles per liter(pmol/L)
Change From Baseline (CFB) in Thyroid Functions: Free Triiodothyronine (T3) and Free Thyroxine (T4)
Picomoles per liter(pmol/L)Dostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Triiodothyronine, Free, Baseline4.48026 ± 1.6387464.48540 ± 1.066597
Triiodothyronine, Free, CFB to Cycle 2 Day 1-0.12423 ± 2.071042-0.24330 ± 1.026993
Triiodothyronine, Free, CFB to Cycle 4 Day 1-0.00187 ± 2.206972-0.11796 ± 1.413190
Triiodothyronine, Free, CFB to Cycle 6 Day 1-0.15030 ± 2.128584-0.37705 ± 1.117516
Triiodothyronine, Free, CFB to Cycle 8 Day 10.11483 ± 2.738875-0.43073 ± 1.123017
Triiodothyronine, Free, CFB to Cycle 10 Day 1-0.25993 ± 2.187046-0.23819 ± 1.273369
Triiodothyronine, Free, CFB to Cycle 12 Day 1-0.04347 ± 2.8174655.82171 ± 34.328615
Triiodothyronine, Free, CFB to Cycle 14 Day 1-0.61895 ± 2.558169-0.33501 ± 1.597219
Triiodothyronine, Free, CFB to Cycle 16 Day 1-0.44645 ± 2.274173-0.36614 ± 1.108135
Triiodothyronine, Free, CFB to Cycle 18 Day 1-0.37234 ± 2.414983-0.12607 ± 1.337185
Triiodothyronine, Free, CFB to Cycle 20 Day 1-0.37506 ± 2.495642-0.26936 ± 1.237097
Triiodothyronine, Free, CFB to Cycle 22 Day 1-0.36400 ± 2.759103-0.17980 ± 1.018812
Triiodothyronine, Free, CFB to Cycle 24 Day 1-0.69144 ± 2.662922-0.18380 ± 0.736262
Triiodothyronine, Free, CFB to Cycle 26 Day 10.01392 ± 1.331466-0.39401 ± 0.669173
Triiodothyronine, Free, CFB to Cycle 28 Day 1-0.05502 ± 1.094085-0.28233 ± 0.880805
Triiodothyronine, Free, CFB to Cycle 30 Day 10.11929 ± 1.151771-0.19119 ± 0.911551
Triiodothyronine, Free, CFB to Cycle 32 Day 10.54114 ± 1.0439160.03556 ± 1.067239
Triiodothyronine, Free, CFB to Cycle 34 Day 10.62534 ± 0.957105-0.32236 ± 0.774334
Triiodothyronine, Free, CFB to End of Treatment-0.64275 ± 2.184114-0.40528 ± 1.086922
Thyroxine, Free, Baseline16.33405 ± 4.29424615.93013 ± 3.436512
Thyroxine, Free, CFB to Cycle 2 Day 1-0.35227 ± 4.2578660.21349 ± 3.541952
Thyroxine, Free, CFB to Cycle 4 Day 10.04265 ± 6.2451670.08969 ± 4.015042
Thyroxine, Free, CFB to Cycle 6 Day 1-0.10229 ± 5.418010-0.58695 ± 3.404576
Thyroxine, Free, CFB to Cycle 8 Day 1-1.02504 ± 6.1687550.27944 ± 3.877876
Thyroxine, Free, CFB to Cycle 10 Day 1-1.15108 ± 5.5863830.08349 ± 3.613602
Thyroxine, Free, CFB to Cycle 12 Day 1-0.16670 ± 6.0817534.71828 ± 27.489015
Thyroxine, Free, CFB to Cycle 14 Day 10.32703 ± 6.114475-0.45213 ± 4.196576
Thyroxine, Free, CFB to Cycle 16 Day 1-0.45337 ± 4.8404400.24537 ± 3.472618
Thyroxine, Free, CFB to Cycle 18 Day 10.07645 ± 5.5247890.47690 ± 1.984139
Thyroxine, Free, CFB to Cycle 20 Day 1-0.41084 ± 5.0132700.37830 ± 3.413511
Thyroxine, Free, CFB to Cycle 22 Day 1-0.65956 ± 5.5628020.45462 ± 2.841910
Thyroxine, Free, CFB to Cycle 24 Day 1-0.71092 ± 6.3143520.31032 ± 2.653193
Thyroxine, Free, CFB to Cycle 26 Day 1-0.89968 ± 5.2463000.23139 ± 3.443957
Thyroxine, Free, CFB to Cycle 28 Day 1-0.89658 ± 5.4891301.10907 ± 2.849631
Thyroxine, Free, CFB to Cycle 30 Day 1-1.46126 ± 4.811596-0.21286 ± 3.203649
Thyroxine, Free, CFB to Cycle 32 Day 1-1.81377 ± 5.4741970.13236 ± 3.519557
Thyroxine, Free, CFB to Cycle 34 Day 1-1.52641 ± 6.3791630.45041 ± 2.435328
Thyroxine, Free, CFB to End of Treatment0.26660 ± 3.8823150.46964 ± 3.310829
SecondaryChange From Baseline in Thyroid Function: Thyrotropin (TSH)

Blood samples were collected for the assessment of Thyroid Function Thyrotropin (TSH).

Time frame:
Up to approximately 46 months
Reported as:
Mean · Milli-international Units/ Liter
Change From Baseline in Thyroid Function: Thyrotropin (TSH)
Milli-international Units/ LiterDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Baseline1.853 ± 1.83541.904 ± 1.7421
CFB to Cycle 2 Day 10.225 ± 3.7642-0.497 ± 1.7405
CFB to Cycle 4 Day 11.285 ± 9.4283-0.622 ± 1.7892
CFB to Cycle 6 Day 11.123 ± 8.45962.006 ± 21.0213
CFB to Cycle 8 Day 12.454 ± 9.72352.648 ± 22.9952
CFB to Cycle 10 Day 13.233 ± 12.15711.986 ± 12.8377
CFB to Cycle 12 Day 12.448 ± 9.85901.138 ± 10.9780
CFB to Cycle 14 Day 11.282 ± 4.25661.734 ± 9.0539
CFB to Cycle 16 Day 11.551 ± 4.79822.056 ± 13.4532
CFB to Cycle 18 Day 11.190 ± 4.1837-0.406 ± 1.6364
CFB to Cycle 20 Day 11.685 ± 5.35171.825 ± 11.8029
CFB to Cycle 22 Day 11.428 ± 5.95121.794 ± 10.5658
CFB to Cycle 24 Day 10.993 ± 3.03722.161 ± 10.7015
CFB to Cycle 26 Day 11.029 ± 4.30802.050 ± 11.8067
CFB to Cycle 28 Day 11.204 ± 3.49021.760 ± 9.6622
CFB to Cycle 30 Day 11.615 ± 5.49663.468 ± 15.7231
CFB to Cycle 32 Day 11.824 ± 4.94230.365 ± 0.8151
CFB to Cycle 34 Day 11.081 ± 2.4504-0.189 ± 1.5062
CFB to End of Treatment2.210 ± 8.38671.303 ± 9.3590
SecondaryChange From Baseline in Thyroid Functions: Triiodothyronine (T3) and Thyroxine (T4)

Blood samples were collected for the assessment of Triiodothyronine (T3) and Thyroxine (T4).

Time frame:
Up to approximately 46 months
Reported as:
Mean · Nanomoles per liter (nmol/L)
Change From Baseline in Thyroid Functions: Triiodothyronine (T3) and Thyroxine (T4)
Nanomoles per liter (nmol/L)Dostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Triiodothyronine, Baseline1.68399 ± 0.3084041.48287 ± 0.526037
Triiodothyronine, CFB to Cycle 2 Day 10.06903 ± 0.172873-0.58292
Triiodothyronine, CFB to Cycle 4 Day 1-0.41878 ± 0.353613—
Triiodothyronine, CFB to Cycle 6 Day 1-0.21476—
Thyroxine, Baseline72.72912 ± 46.84556485.29069 ± 38.027652
Thyroxine, CFB to Cycle 2 Day 116.06393 ± 38.489073-3.12689 ± 11.544100
Thyroxine, CFB to Cycle 4 Day 110.16002 ± 47.74676412.22592 ± 30.578995
Thyroxine, CFB to Cycle 6 Day 19.83083 ± 30.658114-2.45916 ± 27.497527
Thyroxine, CFB to Cycle 8 Day 121.85010 ± 44.242770-0.06812 ± 24.146111
Thyroxine, CFB to Cycle 10 Day 132.19186 ± 41.441071-0.03002 ± 16.413851
Thyroxine, CFB to Cycle 12 Day 123.45510 ± 36.165686-0.82919 ± 9.539787
Thyroxine, CFB to Cycle 14 Day 114.79794 ± 35.6145080.64908 ± 12.623292
Thyroxine, CFB to Cycle 16 Day 121.23230 ± 38.2206657.86174 ± 18.910608
Thyroxine, CFB to Cycle 18 Day 118.35801 ± 31.4363167.37470 ± 8.635752
Thyroxine, CFB to Cycle 20 Day 126.94600 ± 47.91525716.06215 ± 18.656008
Thyroxine, CFB to Cycle 22 Day 122.73866 ± 34.20289018.57057 ± 22.383758
Thyroxine, CFB to Cycle 24 Day 124.31027 ± 45.96334523.08569 ± 20.160509
Thyroxine, CFB to Cycle 26 Day 132.22436 ± 62.12210535.71425 ± 12.285627
Thyroxine, CFB to Cycle 28 Day 121.13316 ± 46.35129220.55189 ± 17.985775
Thyroxine, CFB to Cycle 30 Day 119.12904 ± 53.35152613.09008 ± 11.862148
Thyroxine, CFB to Cycle 32 Day 119.99271 ± 58.50007916.73184 ± 23.660023
Thyroxine, CFB to Cycle 34 Day 1-4.97280 ± 8.6224990.01300
Thyroxine, CFB to End of Treatment11.06954 ± 35.7924554.67311 ± 29.791225
SecondaryNumber of Participants With Worst-case Grade Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

DBP and SBP were measured in a semi-supine position after 5 minutes rest. Grades were derived based on numeric criteria as defined in Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Systolic Blood Pressure (SBP): Grade 0 (\<120 Millimetre of mercury (mmHg)), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). Diastolic Blood Pressure (DBP): Grade 0 (\<80 mmHg), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Only those participants with grade increase have been presented. Participants with missing Baseline values were assumed to have a Baseline value of G0.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Grade Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
DBP, Increase to Grade 13627
DBP, Increase to Grade 23525
DBP, Increase to Grade 367
SBP, Increase to Grade 12418
SBP, Increase to Grade 23424
SBP, Increase to Grade 3811
SecondaryNumber of Participants With Worst Case Pulse Rate Results Post-Baseline Relative to Baseline Based on Potential Clinical Importance (PCI)

Normal range of Pulse Rate was 60 to 100 beats/min. Participants were counted in worst case category that their value changes to low, to within \[w/in\] Range or No Change \[NC\] or high, unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Pulse Rate Results Post-Baseline Relative to Baseline Based on Potential Clinical Importance (PCI)
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
To Low53
To w/in Range or No Change105103
To High79
SecondaryNumber of Participants With Worst-Case Post-Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status

Performance status was assessed using the ECOG scale (Grade 0-5). Grades: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory, able to carry out work of light nature. 2: Ambulatory, capable of self-care, unable to carry out work activities. Up and about more than 50% waking hours. 3: Capable of limited self-care, confined to bed/chair more than 50% waking hours. 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed/chair. 5: Dead.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants With Worst-Case Post-Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
01520
17057
22420
3414
4-554
SecondaryMean Change From Baseline in Electrocardiogram (ECG) Parameters

Participants were in a supine or semi recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs were recorded. Single 12-lead ECG was recorded using an ECG machine. PR, QRS, QT, QTcF, and RR intervals were recorded

Time frame:
Baseline (Day 1), Cycle 1 Day 1, and end of treatment (Up to approximately 46 months)
Reported as:
Mean · Millisecond (msec)
Mean Change From Baseline in Electrocardiogram (ECG) Parameters
Millisecond (msec)Dostarlimab + ChemotherapyPembrolizumab + Chemotherapy
PR Interval, Baseline157.3 ± 26.87152.4 ± 25.54
PR Interval, CFB to Cycle 1 Day 1-6.0 ± 1.418.7 ± 16.17
PR Interval, CFB to End of Treatment-5.3 ± 23.350.2 ± 17.49
QRS Duration, Baseline87.9 ± 14.8589.0 ± 14.91
QRS Duration, CFB to Cycle 1 Day 110.0 ± 13.086.0 ± 14.14
QRS Duration, CFB to End of Treatment3.3 ± 17.14-1.1 ± 13.47
QT Interval, Baseline370.4 ± 35.29374.3 ± 38.05
QT Interval, CFB to Cycle 1 Day 1-19.5 ± 48.23-27.3 ± 57.98
QT Interval, CFB to End of Treatment-1.7 ± 36.57-4.1 ± 38.07
QTcB Interval, Baseline459.3 ± 190.83440.4 ± 121.20
QTcB Interval, CFB to Cycle 1 Day 1-309.0 ± 559.52-31.7 ± 49.81
QTcB Interval, CFB to End of Treatment-12.2 ± 176.21-3.1 ± 30.81
QTcF Interval, Baseline406.6 ± 50.60412.9 ± 48.99
QTcF Interval, CFB to Cycle 1 Day 1-12.3 ± 48.19-4.7 ± 4.16
QTcF Interval, CFB to End of Treatment1.4 ± 65.82-10.0 ± 60.00
RR Interval, Baseline741.3 ± 205.25766.5 ± 195.43
RR Interval, CFB to Cycle 1 Day 181.3 ± 256.20-10.7 ± 81.05
RR Interval, CFB to End of Treatment-3.3 ± 183.712.5 ± 193.04
SecondaryMean Change From Baseline in ECG Mean Heart Rate

Participants were in a supine or semi recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs were recorded. Single 12-lead ECG was recorded using an ECG machine. Mean Heart rate were recorded.

Time frame:
Baseline (Day 1), Cycle 1 Day 1, and end of treatment (Up to approximately 46 months)
Reported as:
Mean · beats/min
Mean Change From Baseline in ECG Mean Heart Rate
beats/minDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Baseline79.8 ± 15.1780.0 ± 16.14
CFB to Cycle 1 Day 10.0 ± 13.043.3 ± 13.65
CFB to End of Treatment1.5 ± 14.710.6 ± 17.95
SecondaryNumber Participant Who Used Concomitant Medications

Number of participants received concomitant medications were summarized.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number Participant Who Used Concomitant Medications
ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Number Participant Who Used Concomitant Medications121122
PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had a confirmed complete response (CR) or confirmed partial response (PR) as their best overall response (BOR) recorded from the date of randomization until disease progression or initiation of new anti-cancer therapy, whichever is earlier based on blinded independent central review (BICR) evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters (e.g., percent change from baseline).

Time frame:
Up to approximately 20 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
Objective Response Rate (ORR)46 (37.2 to 55.6)37 (28.3 to 46.1)
Statistical analysis
  • Dostarlimab + Chemotherapy vs Pembrolizumab + Chemotherapy · Difference in response rate: 9.32 · 80% CI 1.46 to 17.18Mantel and Haenszel method with Sato's variance estimator was used for between arms comparison and was stratified by PD-L1 status and smoking status based on the strata data collected in interactive response technology (IRT) at randomization

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 and up to approximately 46 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dostarlimab + Chemotherapy80/121 (66.1%)51/121 (42.1%)117/121 (96.7%)
Pembrolizumab + Chemotherapy91/122 (74.6%)61/122 (50%)114/122 (93.4%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
PneumoniaInfections and infestations4/12115/122
AnaemiaBlood and lymphatic system disorders9/1216/122
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1214/122
PneumonitisRespiratory, thoracic and mediastinal disorders3/1215/122
Febrile neutropeniaBlood and lymphatic system disorders4/1214/122
COVID-19Infections and infestations4/1213/122
Pleural effusionRespiratory, thoracic and mediastinal disorders4/1211/122
PyrexiaGeneral disorders1/1214/122
ThrombocytopeniaBlood and lymphatic system disorders3/1213/122
AstheniaGeneral disorders3/1211/122
Most frequent other events
Showing 10 of 44
Most frequent other events
EventDostarlimab + ChemotherapyPembrolizumab + Chemotherapy
AnaemiaBlood and lymphatic system disorders63/12159/122
AstheniaGeneral disorders41/12142/122
NauseaGastrointestinal disorders31/12132/122
CoughRespiratory, thoracic and mediastinal disorders26/12122/122
ConstipationGastrointestinal disorders24/12126/122
VomitingGastrointestinal disorders25/12116/122
NeutropeniaBlood and lymphatic system disorders22/12125/122
Decreased appetiteMetabolism and nutrition disorders24/12120/122
DyspnoeaRespiratory, thoracic and mediastinal disorders22/12121/122
DiarrhoeaGastrointestinal disorders21/12117/122

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Dostarlimab + ChemotherapyPembrolizumab + ChemotherapyTotal
Mean63.4 ± 9.4365.4 ± 8.5164.4 ± 9.02
Sex: Female, Male
Sex: Female, Male(Participants)Dostarlimab + ChemotherapyPembrolizumab + ChemotherapyTotal
Female364581
Male8577162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dostarlimab + ChemotherapyPembrolizumab + ChemotherapyTotal
American Indian or Alaska Native101
Asian232144
Black or African American134
White8784171
Multiple336
Not Reported257
Unknown4610
08

Study locations

58 sites
  • GSK Investigational Site
    Denver, North Carolina 80128, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45242, United States
  • GSK Investigational Site
    Fairfax, Virginia 22031, United States
  • GSK Investigational Site
    Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1012AAR, Argentina
  • GSK Investigational Site
    Córdoba, X5004FHP, Argentina
  • GSK Investigational Site
    Florida, 1602, Argentina
  • GSK Investigational Site
    La Plata, 1900, Argentina
  • GSK Investigational Site
    La Rioja, F5300COE, Argentina
  • GSK Investigational Site
    Pergamino, B2700CPM, Argentina
  • GSK Investigational Site
    Rosario, S2000KZE, Argentina
  • GSK Investigational Site
    San Juan, J5402DIL, Argentina
  • GSK Investigational Site
    Viedma, R8500ACE, Argentina
  • GSK Investigational Site
    Barretos, 14784-400, Brazil
  • GSK Investigational Site
    Fortaleza, 60336-232, Brazil
  • GSK Investigational Site
    Natal, 59075-740, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20230 -130, Brazil
  • GSK Investigational Site
    São Paulo, 04014-002, Brazil
  • GSK Investigational Site
    Vitória, 29043-260, Brazil
  • GSK Investigational Site
    Santiago, 7500653, Chile
  • GSK Investigational Site
    Santiago, 8320000, Chile
  • GSK Investigational Site
    Caen, 14033, France
  • GSK Investigational Site
    Le Mans, 72000, France
  • GSK Investigational Site
    Limoges, 87042, France
  • GSK Investigational Site
    Pessac, 33604, France
  • GSK Investigational Site
    Saint-Herblain, 44805, France
  • GSK Investigational Site
    Valenciennes, 59300, France
  • GSK Investigational Site
    Berlin, 12200, Germany
  • GSK Investigational Site
    Cologne, 51109, Germany
  • GSK Investigational Site
    Frankfurt, 60488, Germany
  • GSK Investigational Site
    Immenhausen, 34376, Germany
  • GSK Investigational Site
    Oldenburg, 26121, Germany
  • GSK Investigational Site
    Aviano PN, 33081, Italy
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Milan, 20141, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Roma, 00152, Italy
  • GSK Investigational Site
    Bydgoszcz, 85-796, Poland
  • GSK Investigational Site
    Lodz, 90-338, Poland
  • GSK Investigational Site
    Lublin, 20-954, Poland
  • GSK Investigational Site
    Olsztyn, 10-357, Poland
  • GSK Investigational Site
    Poznan, 60-693, Poland
  • GSK Investigational Site
    Bucharest, 030442, Romania
  • GSK Investigational Site
    Craiova, 200347, Romania
  • GSK Investigational Site
    Floreşti, 407280, Romania
  • GSK Investigational Site
    Cheongju Chungcheongbuk-do, 28644, South Korea
  • GSK Investigational Site
    Pusan, 48108, South Korea
  • GSK Investigational Site
    Seoul, 05505, South Korea
  • GSK Investigational Site
    Seoul, 06351, South Korea
  • GSK Investigational Site
    Seoul, 120-752, South Korea
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Jaén, 23007, Spain
  • GSK Investigational Site
    Lugo, 27003, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
  • GSK Investigational Site
    Seville, 41014, Spain
  • GSK Investigational Site
    Changhua, 500, Taiwan
  • GSK Investigational Site
    Taipei, 11490, Taiwan
09

References and documents

Publications

  • Austin D, Melhem M, Gandhi Y, Lu S, Visser S. Comparative analysis of PD-1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL-2 stimulation data. CPT Pharmacometrics Syst Pharmacol. 2023 Jan;12(1):87-94. doi: 10.1002/psp4.12878. Epub 2022 Nov 16. PubMed 36317409 ↗
  • Lim SM, Peters S, Ortega Granados AL, Pinto GDJ, Fuentes CS, Lo Russo G, Schenker M, Ahn JS, Reck M, Szijgyarto Z, Huseinovic N, Zografos E, Buss E, Stjepanovic N, O'Donnell S, de Marinis F. Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial. Nat Commun. 2023 Nov 11;14(1):7301. doi: 10.1038/s41467-023-42900-4. PubMed 37951954 ↗
  • Lim SM, Ortega Granados AL, Pinto GDJ, Fuentes CS, Lo Russo G, Schenker M, Ahn JS, de Marinis F, Locke K Jr, Szijgyarto Z, Buss E, Stjepanovic N, Diaz-Padilla I, Peters S. Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC. JTO Clin Res Rep. 2025 Sep 4;6(10):100900. doi: 10.1016/j.jtocrr.2025.100900. eCollection 2025 Oct. PubMed 41080090 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Aug 2022, 20 months.

Results were first posted in Sep 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2020
First posted
Oct 9, 2020
StartActual
Nov 19, 2020
Primary completionActual
Aug 4, 2022
CompletionActual
Sep 10, 2024
Results first posted
Sep 18, 2023
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04581824
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 9, 2020
Start date
Nov 19, 2020
Primary completion
Aug 4, 2022
Completion
Sep 10, 2024
Results posted
Sep 18, 2023
Last update
Aug 8, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion